Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Estonia

Coordination and Support Action · Running

VECTIOPEP First-in-class mRNA-based therapeutic cancer vaccine

Coordinator
vectiopep OU, Estonia
Runs
1 June 2026 to 31 May 2028
Status
Running
EU funding
€500k
Total cost
—
Partners
1 organisations in 1 countries
Type
Coordination and Support Action
Grant agreement
101310528

What the project is doing

In the project's own words, from its summary on CORDIS.

Immunotherapy is revolutionising cancer treatment, providing advantages over traditional chemotherapy. Instead of injection of toxic chemical compounds, immunotherapy activates body's native defences to kill abnormal tissues, such as cancer cells. In addition, activated immune system offers long term protection against recurrence of cancer. However, current immunotherapies – Immune Checkpoint Inhibitors and CAR T – have reached critical limitations: the incredible effects are only achieved in select cases and further innovation is only incremental.

Thus, to make immunotherapy universal, a qualitative leap is required.mRNA as a therapeutic has the potential to create the next level cancer immunotherapy, serious challenges remain. mRNA needs a delivery system that helps it reach the interior of the specific immune cells, but the current-state-of-the-art delivery technology is LNP (lipid nanoparticles), accumulates mRNA off-target into liver, where it has no impact on neither immune system activation nor tumours.

Vectiopep has developed a precision drug delivery method that enables selective transport of mRNA into the patients' immune cells in spleen. The proprietary delivery technology relies on natural, biodegradable peptides, offering an advantage over artificial lipids. By combining the precision delivery with the capacity of a single mRNA to encode multiple antigens, Vectiopep can simultaneously educate and activate powerful killer immune cells for a robust, multi-pronged attack on cancer.

Vectiopep has demonstrated in several aggressive animal tumour models that the technology treats cancer, is effective even at low doses, and has long-lasting effects. Thus, the technology has the potential to bring about the required qualitative leap in cancer immunotherapy.

Topics

Who is involved

OrganisationCityCountryRole
vectiopep OUKulitse alevikEstoniaCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI